SMAD4 and pancreatic neoplasm: CRISPR-mediated ablation of KLF5, SMAD4, or EGFR in pancreatic tumor cells leads to increased T-cell infiltration and improved combination immunotherapy response with gemcitabine, abraxane, CD40 agonistic antibody, CTLA4-blocking antibody, and PD-1-blocking antibody (named as GAFCP) [28].